SCHEMBL14715019

SCHEMBL14715019

Cn1cnc(CNC(=O)C(NC(=O)c2ccc(-c3ccc(OCCO)cc3)cc2)C(=O)NO)c1

nearest known ligand 0.43

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.42
HPGDS O60760 1/20 0.42
PPARG P37231 1/20 0.40
SCN9A Q15858 2/20 0.39
EGLN2 Q96KS0 1/20 0.38
ALDH1A1 P00352 1/20 0.37
TBXAS1 P24557 2/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MAPK14 Q16539 1/20 0.36
SMO Q99835 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14714539 0.85 HPGDS (0.42) HRH3HPGDSPPARGALDH1A1TBXAS1
SCHEMBL14714513 0.83 HRH3 (0.42) HRH3PPARGEGLN2ALDH1A1HSD17B10
SCHEMBL14715228 0.82 HRH3 (0.41) HRH3PPARGTBXAS1
SCHEMBL14715017 0.82 HPGD (0.55) ALDH1A1HPGDHSD17B10MAPK14
SCHEMBL14715049 0.82 PPARG (0.51) HRH3PPARG
SCHEMBL14715334 0.81 CHRNB2 (0.43) HRH3PPARGALDH1A1HPGDHSD17B10
SCHEMBL14715281 0.81 HRH3 (0.42) HRH3HPGDSPPARGTBXAS1
SCHEMBL14715222 0.81 PPARG (0.39) HRH3PPARGALDH1A1HPGDHSD17B10
SCHEMBL14715425 0.81 PPARG (0.50) HRH3PPARG
SCHEMBL14715050 0.81 NPC1 (0.41) HRH3PPARGALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2562155-B1 HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO LTD (JP) 2019-06-05 EP disclosed
US-9499477-B2 Hydroxamic acid derivative TOYAMA CHEMICAL CO., LTD. (JP) 2016-11-22 US disclosed
US-9499477-B2 Hydroxamic acid derivative TOYAMA CHEMICAL CO., LTD. (JP) 2016-11-22 US disclosed
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 US disclosed
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 US disclosed
US-9073821-B2 Hydroxamic acid derivative TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-07-07 US disclosed
US-9073821-B2 Hydroxamic acid derivative TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-07-07 US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 US disclosed
EP-2562155-A1 NOVEL HYDROXAMIC ACID DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-02-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE LCT, AGXT, HDAC9 HRH3 1334/4885HPGDS 166/4885PPARG 972/4885
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE LCT, AGXT, HDAC9 HRH3 1334/4885HPGDS 166/4885PPARG 972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.